Vivos Therapeutics Q3 2026 Earnings Call Transcript

Key Takeaways

  • Neutral Sentiment: Revenue fell 5% year over year to $6.4 million in Q3, and gross margin declined to 52% from 58%, partly reflecting lower product sales as Vivos shifts away from VIPs. For the first nine months, revenue and gross profit each rose 23%, driven by 57% growth in service revenue.
  • Positive Sentiment: Cost reductions helped narrow Q3 operating loss by 18% to $3.9 million, while general and administrative and sales and marketing expenses together fell $1.6 million year over year. Net loss improved to $2.0 million, though that result included a one-time benefit of about $2.9 million from reversing an Employee Retention Credit liability.
  • Positive Sentiment: Management said monthly new-patient referrals to its two Nevada treatment centers have nearly quadrupled since May and expects payer renegotiations to potentially add about $3.8 million in annual revenue, before any increase in patient volume. It also expects new clinical services and payer initiatives to contribute more in Q4 and 2027, but those outcomes depend on execution, reimbursement, and patient participation.
  • Negative Sentiment: Liquidity remains a major risk: Vivos had about $0.2 million in cash at quarter-end, used $12.3 million in operating cash in the first nine months, and said it needs additional financing. The company warned that without financing there is substantial doubt about its ability to continue as a going concern.
  • Negative Sentiment: Vivos remains out of compliance with Nasdaq’s $1 minimum bid-price requirement, with a compliance deadline of December 4, 2026; the company said its shares have recently traded below $0.10, which could trigger suspension and delisting proceedings. Stockholders are scheduled to vote on a proposed reverse stock split intended to address the bid-price issue.
AI Generated. May Contain Errors.
Earnings Conference Call
Vivos Therapeutics Q3 2026
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

Good day, everyone, and welcome to the Vivos Therapeutics third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the call over to Roman Franklin, Vivos' Chief Financial Officer, for introductions and the reading of the safe harbor statement. Please go ahead.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Thank you, operator. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With me on the call is Kirk Huntsman, Vivos' Chairman and Chief Executive Officer. Today, we'll review the financial results for the third quarter of 2026, as well as more recent developments and Vivos' plans for the rest of 2026 and beyond. Our earnings press release published today compares mainly the third quarter of 2026 against the second quarter of 2026 to highlight the impact of our efforts to increase revenue and cut costs. You should review the earnings press release together with our quarterly reports on Form 10-Q for the quarters ended September 30th, 2026, and June 30th, 2026.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events and our future financial and operating performance. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant risk, uncertainties, and contingencies, many of which are beyond the company's control.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Actual results, including without limitation, the results of Vivos' growth strategies, operational plans, including sales, marketing, distribution, medical sleep provider acquisition and integration, research and development, regulatory initiatives, cost savings plans, and plans to generate revenue, as well as future potential results of operations or operating metrics, such as the potential for Vivos to achieve future positive cash flows or profitability, and other matters to be addressed by Vivos management in this conference call, may differ materially and adversely from those expressed or implied by such forward-looking statements.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described and other disclosures contained in Vivos' filings with the Securities and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended December 31st, 2025, and our other filings with the SEC, including our third quarter 10-Q filed with the SEC today, all of which are or will be accessible on the Investor Relations section of Vivos' website, as well as the SEC's website.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Forward-looking statements speak only as of the date of this call. Except to the extent required by law, Vivos assumes no obligation to update statements as circumstances change. Finally, please be aware that the U.S. Food and Drug Administration has given certain specific Vivos appliances 510(k) clearance to treat mild to severe obstructive sleep apnea in adults. With the FDA clearance of certain Vivos products for severe OSA in November 2023, treatment of patients with severe OSA with these specific appliances no longer need to be performed off-label at the clinical discretion of the treating doctor and is now an integral part of the Vivos treatment protocol. Treatment of OSA of any severity or any other condition with any other of Vivos' FDA-cleared devices remains at the clinical discretion of the treating doctor.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

For further information on our results for the three and nine-month periods ended September 30th, 2026, please see our earnings release, which was distributed earlier today, and our quarterly reports on Form 10-Q, which are available on the SEC filings portion of the Investor Relations section of our website.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

In the third quarter of 2026, Vivos completed its fifth full quarter of activity following our June 10th, 2025 acquisition of The Sleep Center of Nevada. This is the first quarter in which our year-over-year comparison includes a full quarter of SCN operations in both periods. During the quarter, we remained focused on reducing operating costs, strengthening our balance sheet, and building the clinical lines we believe will drive revenue and margin going forward. Revenue decreased by approximately $0.4 million or 5% to approximately $6.4 million for the three months ended September 30th, 2026, compared to $6.8 million for the three months ended September 30th, 2025, which was our first full quarter following the SCN acquisition.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Product revenue decreased by approximately $0.4 million to approximately $1.8 million, reflecting lower appliance sales to our VIPs as a result of our strategic pivot away from VIPs to sleep centers, while service revenue increased by 1% to approximately $4.6 million. For the nine months ended September 30th, 2026, revenue increased by approximately $3.1 million or 23% to $16.7 million compared to $13.6 million for the nine months ended September 30th, 2025. The increase in total revenue during the period was driven by an increase of approximately $4.4 million or 57% in service revenue, offset by a decrease of approximately $1.3 million in product revenue.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

The decrease in product revenue was attributable to lower sales volume of our on-demand orthodontic devices to VIP members, again, due to our strategic pivot, while the increase in service revenue reflects new patients being treated at our Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada. Cost of sales increased $0.3 million or 9% to approximately $3.1 million for the three months ended September 30th, 2026, compared to $2.8 million for the three months ended September 30th, 2025. This is primarily attributable to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers. For the nine months ended September 30th, 2026, cost of sales increased $1.3 million or 22% to $7.4 million compared to $6.1 million for the nine months ended September 30th, 2025.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

This is primarily related to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers. For the three months ended September 30th, 2026, gross profit decreased by approximately $0.6 million to $3.3 million. This decrease was attributable to the decrease in revenue of approximately $0.4 million and the increase in cost of sales of $0.3 million. Gross margin decreased to 52% for the three months ended September 30th, 2026, compared to 58% for the three months ended September 30th, 2025, due to the decrease in product revenue. For the nine months ended September 30th, 2026, gross profit increased by $1.8 million or 23% to $9.3 million. This increase is attributable to the increase in revenue of $3.1 million, partially offset by the increase in cost of sales of $1.3 million.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Gross margin increased to 56% for the nine months ended September 30th, 2026, compared to 55% for the nine months ended September 30th, 2025. General and administrative expenses decreased $1.4 million or 18% to approximately $6.5 million for the three months ended September 30th, 2026, as compared to $7.9 million for the three months ended September 30th, 2025. The decrease is primarily attributable to a $0.8 million reduction in professional fees, a $0.3 million reduction in equipment maintenance, a $0.2 million decrease in office expenses and supplies, and a $0.1 million decrease in infrastructure expenses. This reflects our continued focus on cost reduction and the absence of certain integration costs incurred in the prior year period following the acquisition of SCN.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

For the nine months ended September 30th, 2026, general and administrative expenses increased by $3.4 million or 17% to $22.5 million as compared to $19.2 million for the nine months ended September 30th, 2025. The primary driver of this increase related to the costs associated with establishing our two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada, including an increase in salaries and related compensation of $1.7 million, an increase of $0.9 million in professional fees, an increase in occupancy expenses of $0.6 million, and other costs of $0.3 million. Sales and marketing expenses decreased $0.2 million or 48% to approximately $0.2 million for the three months ended September 30th, 2026, as compared to $0.4 million for the three months ended September 30th, 2025, which is attributable in significant part to our focus on reducing costs.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Sales and marketing expenses decreased by $0.4 million to $0.6 million for the nine months ended September 30th, 2026, compared to $1 million for the nine months ended September 30th, 2025. This decrease was primarily driven by our decrease in sales and marketing campaigns, lower commissions paid to our employees for digital media services, and reduction in use of marketing supplies. The depreciation and amortization expense increased $0.2 million for the three months ended September 30th, 2026, and increased $0.6 million to $1.5 million for the nine months ended September 30th, 2026, from $0.9 million for the nine months ended September 30th, 2025. Depreciation and amortization increased due to assets being placed into service during the period.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Other expense increased $0.3 million for the quarter and $2.3 million year-to-date, primarily due to interest expense, including interest expense on short-term financing agreements entered into in the third quarter. This was more than offset by an increase in other income of $2.9 million for the quarter and $3.2 million year-to-date. The increase in other income is primarily attributable to the reversal of our previously recorded Employee Retention Credit liability of approximately $2.9 million. Management concluded that repayment of the credits is no longer deemed probable. Year-to-date, other income also includes $0.3 million related to the valuation change and the earnout related to the acquisition of SCN. The financial statements have been prepared in conformity with generally accepted accounting principles, which contemplates continuation of the company as a going concern.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

We've incurred losses since inception, including $2 million and $5.4 million for the three months ended September 30th, 2026, and 2025 respectively, and $15.2 million and $14.3 million for the nine months ended September 30th, 2026, and 2025 respectively, resulting in an accumulated deficit of approximately $140.5 million as of September 30th, 2026. Net cash used in operating activity amounted to approximately $12.3 million and $11.5 million for the nine months ended September 30th, 2026, and 2025 respectively.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

As of September 30th, 2026, we had total liabilities of approximately $20.7 million, down from $26.7 million at December 31st, 2025. As of September 30th, 2026, we had approximately $0.2 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next 12 months from the date of issuance of the finance statements included in our Form 10-Q.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Without additional financing, these factors raise substantial doubt regarding the company's ability to continue as a going concern. As of September 30th, 2026, we also had approximately $2.3 million of outstanding principal under our senior secured note with Streeterville Capital, which is due on June 10th, 2027. We have implemented cost savings measures in our legacy business that have reduced cash used in operations. In the latter part of the third quarter and through the present date, we have continued to reduce operating costs and streamline operations, and we estimate that we have eliminated over $5 million in annual operating costs, with further cuts and efficiencies still being worked on. During the first nine months of 2025, many one-time costs related to the acquisition of SCN were recognized and were not recurring in 2026.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

During 2026, we have taken steps to strengthen our balance sheet, including raising equity capital into the first three quarters of 2026 and exchanging approximately $6.1 million of senior secured debt held by Streeterville Capital for equity. In the third quarter, we exchanged $3.25 million of principal for common stock and Series B non-convertible preferred stock on August 4th, 2026, and further, approximately $2.9 million of principal for common stock on September 2nd, 2026. We have funded our operations through equity raises and debt financings during the nine months ended September 30th, 2026, and fiscal year ended December 31st, 2025, and we will need additional financing to satisfy our cash needs as we seek to increase revenue with a view towards ultimately achieving positive cash flow from operations.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

Our stockholders' equity at September 30th, 2026, is approximately $2.4 million, below Nasdaq's $2.5 million minimum stockholders' equity requirement. On October 16th, 2026, we completed the SOD Sciences transaction, issuing 12,000 shares of Series C convertible preferred stock in exchange for an equity interest in SOD Sciences and a 50% co-ownership interest in its pseudohypoxia early warning test and related intellectual property. Based on our Form 8-K filed October 19th, 2026, Nasdaq notified us on October 20th, 2026, that we have regained compliance with the stockholders' equity requirement, subject to Nasdaq's continued monitoring, and if we do not evidence compliance in our next periodic report, we may be subject to delisting. The accounting for the SOD Sciences transaction remains subject to completion of the purchase price allocation and review by our independent registered public accounting firm.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

We also remain out of compliance with Nasdaq's $1 minimum bid price requirement, and our compliance period to regain compliance runs through December 4th, 2026. Our common stock has recently traded below $0.10 per share. Under Nasdaq rules, if the closing bid price of our common stock is $0.10 or less for 10 consecutive business days, Nasdaq must issue a delisting determination and suspend trading in our common stock with no period to regain compliance, and a request for a hearing would not stop the suspension.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

At our annual meeting on that date, our stockholders will vote on a proposed reverse stock split intended to address the bid price requirement, on the issuance of common stock upon conversion of the Series C convertible preferred stock above Nasdaq's 19.99% exchange cap, and on the other proposals described in our proxy statement.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

In summary, our third quarter results reflect the progress we are making on cost discipline. Operating loss improved by $0.8 million, or 18%, to $3.9 million, and general and administrative and sales and marketing expenses together declined by $1.6 million compared to the prior year quarter. Net loss improved by $3.4 million to $2 million, which includes the approximately $2.9 million benefit from the reversal of our Employee Retention Credit liability. For the first nine months of 2026, revenue and gross profit each grew by 23%, driven by a 57% increase in service revenue. At the same time, gross margin declined to 52% in the quarter as product revenue continued to decline with our strategic pivot, and our liquidity position remains tight.

Roman Franklin
Roman Franklin
CFO at Vivos Therapeutics

We are pursuing clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and setup of PAP and CPAP treatments, and remote patient monitoring of CPAP users, as well as the renegotiation of payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027. For more detailed information, I refer you to our earnings release and our full Form 10-Q filed today. With that, I will hand the call over to our Chairman and CEO, Kirk Huntsman, to discuss the progress we have made to date on SCN and Vivos.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

Thank you, Roman. These third quarter results are in line with our prior statements indicating that Q3 would begin to show modest improvement in our operations and financial performance. Revenue grew from the second quarter, operating expenses declined, and our operating loss narrowed, even though the majority of our cost-cutting and revenue initiatives have been occurring here in the fourth quarter. Our primary accomplishment in the third quarter was to better connect sleep diagnosis at SCN with appropriate treatment and continuing care at our two SAMC centers in Las Vegas. As a direct result of those efforts, monthly new patient referral volume at our SAMC centers has increased nearly fourfold over what it was in May of this year.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

Keep in mind that the seven Sleep Center of Nevada, or SCN, locations are primarily focused on diagnosis, whereas the two Sleep and Airway Medicine Centers, what we call SAMC centers, are primarily focused on treatment services. Our two Nevada SAMC centers support medical and dental professionals who offer a full range of treatment options, from CPAP to various oral appliances and adjunctive therapies such as myofunctional and laser therapies. This creates opportunities to serve patients with a full spectrum of options at several stages of care, including evaluation, treatment, and follow-up. Vivos CARE devices remain an important part of that offering. They are FDA cleared for mild to severe obstructive sleep apnea in adults, and our DNA appliance is cleared for specified pediatric patients ages six through 17 with moderate to severe OSA who need orthodontic treatment.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

Treatment selection remains a clinical decision based on each patient's needs and the applicable device indications. As we have previously discussed, our strategic pivot and commercial focus has shifted towards medical practices with established patient populations. The strategy is to build relationships that can support diagnostic services, clinically appropriate treatment, and recurring services over time. The service revenue in our results is but the very beginning of what we expect to see that line item to scale into as we continue to aggressively pursue affiliations with sleep testing centers, sleep medicine practitioners, cardiologists, and other medical practices with growing numbers of sleep disorder patients.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

Meanwhile, our SCN operations in Las Vegas continue to be overhauled, reorganized, restaffed, and streamlined by the introduction of new AI-driven clinical and practice management software, new computer systems, new phone systems, and a new organizational structure geared to increase production capacity while minimizing labor costs. Our operation team estimates that these operating initiatives will potentially double the production capacity at SCN with a 30% lower headcount requirement.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

One important example of our progress at SCN is the overhaul of our call center, where we reduced staff by over 50% and increased call volume capacity by over 400 calls per day. For the first time ever, our SCN call center has been able to handle 100% of the call volume, including callbacks, which some days can be well over 1,000 calls per day. In addition, our Q3 initiative to optimize our payer contracts by renegotiating with nearly all of our commercial payers continues to gain ground and is accelerating here in the fourth quarter, as we are now engaging professional insurance payer negotiators to assist us in this process and to ensure the very best outcomes possible.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

We expect to begin seeing tangible, and in some cases, significant increases in our contract reimbursement rates beginning in this current quarter and scaling rapidly in the first half of 2027. Expected rate increases will vary from payer to payer and from procedure to procedure, but the overall potential revenue lift from this payer contract initiative is expected to approach $3.8 million annually without any increase in patient volumes or services. We have also taken substantial and meaningful action on cost reductions, as Roman described. From the latter part of the third quarter through today, we estimate that we've eliminated more than $5 million in current annual operating costs. These operating costs include reductions in the labor force, as well as eliminating or renegotiating certain vendors and service providers to the company. Additional reductions and efficiencies remain under review.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

The quarter's lower administrative and marketing expenses are an encouraging early result. The next step is to sustain those savings while improving patient throughput, reimbursement, and collections, which we are actively pursuing. Speaking of collection efforts, we have also engaged a professional medical billing agency with collection capabilities. Their efforts have already yielded a material reduction in our overall accounts receivable and a six-figure increase in monthly collections from prior outstanding balances. Several clinical initiatives support our overall objectives.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

For example, we are developing EEG testing and treatment services for insomnia and other non-obstructive sleep apnea sleep disorders, distribution and setup of PAP and CPAP treatments, and remote patient monitoring for CPAP users. These programs allow us to offer additional services to existing patient populations, as well as newly diagnosed patients. Remote monitoring, in particular, offers a potential significant and high-margin recurring revenue opportunity. Its value will depend on eligible patients enrolling, services being delivered appropriately, and reimbursement supporting the cost of care.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

We are focused on those practical requirements as the programs develop. We expect the clinical programs and payer initiatives to contribute materially to revenue and overall margin growth in the fourth quarter of 2026 and increasingly throughout 2027. That expectation, of course, depends on execution, patient participation, payer terms, and access to the capital needed to operate and develop the business. Outside Nevada, our collaboration agreement with South Palm Cardiovascular Associates provides a concrete opportunity to apply the model in South Florida. The practice has an estimated population of more than 31,000 patients across four locations. We intend to establish a Sleep and Airway Medicine Center, what we call a SAMC center, near one of those locations, with operations expected to begin in early 2027.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

That patient population represents a potential source of clinically appropriate testing evaluations and treatment opportunities. That 31,000 is not a count of patients already enrolled in Vivos treatment, just to be clear. Realizing the opportunity here requires facility readiness, staffing, financing, payer arrangements, and successful clinical implementation. We also completed a strategic transaction with SOD Sciences in October, acquiring at least an 11% diluted equity interest in SOD and a 50% co-ownership interest in its pseudohypoxia early warning test and related intellectual property. As Roman mentioned, we issued Series C convertible preferred stock with a $12 million aggregate stated value, which is being carried on the books at some discount to that. No cash in that transaction changed hands. The transaction, however, adds potential diagnostic and commercial opportunities along several fronts.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

The agreement contemplates further marketing arrangements, including potential access through a CLIA-certified laboratory called American Health Associates, based in South Florida, with operations extending across nearly half of the U.S. and to over 3,000 assisted living and nursing home centers. Also with the Cleveland Clinic. The Cleveland Clinic Weston Florida also represents a significant opportunity for Vivos. Definitive agreements with those organizations are pending and not assured, but we are not treating potential channel access as contracted revenue.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

Looking ahead to the future, our objective is positive operating cash flow in early 2027 and beyond. The work supporting that objective is clear and specific. We need to preserve the cost reductions and even go further, as appropriate. We need to improve our reimbursement and collections. We need to develop clinical programs and execute on those programs that will generate an attractive return on the resources they require.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

We believe the combination of our medical provider relationships, our treatment capabilities, and our lower operating costs create a strong basis for progress and for future scalability of the business. The sequential revenue increase and narrower operating losses are important signs of that progress. We appreciate all of our clinicians, our employees, and our partners in the work required to make this transition happen, and we are especially grateful to our shareholders for their continued engagement and support.

Kirk Huntsman
Kirk Huntsman
Chairman and CEO at Vivos Therapeutics

Thank you for joining us today. Our focus is on converting the progress we've made in this quarter into sustained improvement in revenue, margins, and cash flow. We look forward to reporting on that work as we move forward throughout the fourth quarter and into 2027. Stay tuned for further additional announcements as we close out this year and head into next. Thank you again for your support of Vivos. Operator?

Operator

Thank you. This concludes Vivos Therapeutics' third quarter 2026 earnings call. Thank you for participating, and you may now disconnect your line.

Executives
    • Roman Franklin
      Roman Franklin
      CFO
    • Kirk Huntsman
      Kirk Huntsman
      Chairman and CEO